PHAXIAM Provides Business and Financial Update for the Third Quarter of 2023
Conference call and webcast (English) on Wednesday, November 15, 2023at 8:30am ET / 2:30pm CET
Read more
PHAXIAM announced that TP ICAP Midcap, a brokerage firm and investment bank specializing in small and mid-caps has initiated coverage of its shares
News & events
Press release
News
PHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureus
Read more
Press release
PHAXIAM announced that TP ICAP Midcap, a brokerage firm and investment bank specializing in small and mid-caps has initiated coverage of its shares
TP ICAP Midcap began covering the stock with a “Buy” recommendation and valued the Company at €8.5 per share
Read morePress release
PHAXIAM Therapeutics announces high coverage performance of its two anti-Staphylococcus aureus phages over clinical strains
Read more
Press release
PHAXIAM Receives Compliance Notice from Nasdaq
Read more
Press release
PHAXIAM Therapeutics and Vetophage Announce Strategic Research Collaboration
Read more
Press release
PHAXIAM Provides Business and Financial Update – For the First Half of 2023
Read more
Press release
PHAXIAM Therapeutics extends its phage portfolio to Klebsiella pneumoniae, a new resistant and aggressive bacterial target
Read more
Press release
PHAXIAM Therapeutics announces the completion of its reverse share split
Read more
Press release
PHAXIAM Therapeutics publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferences
Read more
Press release
PHAXIAM Therapeutics announces a reverse share split of its shares
Read more
Press release
PHAXIAM Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PHXM
Read more